Literature DB >> 31372282

Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia.

Kota Murohashi1, Yu Hara1, Yusuke Saigusa2, Nobuaki Kobayashi1, Takashi Sato1, Masaki Yamamoto3, Makoto Kudo3, Takeshi Kaneko1.   

Abstract

BACKGROUND: A prognostic factor for patients with acute or subacute idiopathic interstitial pneumonias (IIPs) or acute exacerbation (AE) of collagen vascular diseases-related interstitial pneumonia (CVD-IP) has not been established. We aimed to determine whether the Charlson comorbidity index (CCI) could serve as a prognostic factor for patients with these patients.
METHODS: We assessed baseline prognostic factors among patients with acute or subacute IIPs and AE of CVD-IP who were admitted to hospital between January 2014 and December 2017. We classified them as survivors and non-survivors at 3 months and compared their age, sex, CCI, blood parameters [lactate dehydrogenase (LDH), surfactant protein (SP)-D, Krebs von den Lungen-6, and partial pressure of oxygen in arterial blood/fraction of the inspiratory oxygen], high resolution CT (HRCT) scores and treatment.
RESULTS: Sixty eight patients with (mean age, 75 years), were assessed. All patients received steroid pulse therapy. We found that 45 of acute or subacute IIPs and 16 of AE of CVD-IP were included. Stepwise multivariate analysis selected CCI (OR, 1.306; 95% CI, 1.090-1.573; P=0.004), serum LDH (OR, 1.003; 95% CI, 1.001-1.005; P=0.002), and sex (OR, 8.555; 95% CI, 1.729-154.978; P=0.038) as significant predictors of 3-month mortality among these patients. Three-month mortality was significantly worse among patients with high (≥4) than low (<4) CCI (mortality rates: 63.2% vs. 16.3%, P<0.001). Moreover, the composite scoring system including CCI, serum LDH, and sex was acceptable (Bootstrap AUC, 0.859; Bootstrap C-index, 0.747).
CONCLUSIONS: The composite scoring system including CCI, sex, and serum LDH could be a useful mortality prediction tool for patients with acute or subacute IIPs and AE of CVD-IP requiring steroid pulse therapy.

Entities:  

Keywords:  Composite scoring system; idiopathic pulmonary fibrosis (IPF); lactate dehydrogenase (LDH); mortality; sex

Year:  2019        PMID: 31372282      PMCID: PMC6626781          DOI: 10.21037/jtd.2019.05.46

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  31 in total

1.  Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis.

Authors:  I-Nae Park; Dong Soon Kim; Tae Sun Shim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Won Dong Kim; Se Jin Jang; Thomas V Colby
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

Review 2.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

3.  Cumulative incidence of and predictive factors for lung cancer in IPF.

Authors:  Yuichi Ozawa; Takafumi Suda; Tateaki Naito; Noriyuki Enomoto; Dai Hashimoto; Tomoyuki Fujisawa; Yutaro Nakamura; Naoki Inui; Hirotoshi Nakamura; Kingo Chida
Journal:  Respirology       Date:  2009-07       Impact factor: 6.424

4.  Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Tomoyuki Kakugawa; Shin-Ichi Yokota; Yuji Ishimatsu; Tomayoshi Hayashi; Shota Nakashima; Shintaro Hara; Noriho Sakamoto; Hiroshi Kubota; Mariko Mine; Yasuhiro Matsuoka; Hiroshi Mukae; Kazuhiro Nagata; Shigeru Kohno
Journal:  Cell Stress Chaperones       Date:  2013-02-22       Impact factor: 3.667

5.  Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic.

Authors:  Ryo Tachikawa; Keisuke Tomii; Hiroyuki Ueda; Kazuma Nagata; Shigeki Nanjo; Ayako Sakurai; Kyoko Otsuka; Reiko Kaji; Michio Hayashi; Nobuyuki Katakami; Yukihiro Imai
Journal:  Respiration       Date:  2011-09-06       Impact factor: 3.580

6.  Serum procalcitonin is a valuable diagnostic marker in acute exacerbation of interstitial pneumonia.

Authors:  Kazuma Nagata; Keisuke Tomii; Kojiro Otsuka; Ryo Tachikawa; Atsushi Nakagawa; Kyoko Otsuka; Junpei Takeshita; Kosuke Tanaka; Takeshi Matsumoto; Kazuya Monden; Takahisa Kawamura; Koji Tamai
Journal:  Respirology       Date:  2013-04       Impact factor: 6.424

7.  [Relationship between the prognosis of interstitial pneumonia and its comorbidities].

Authors:  Katsutoshi Ando; Yoshihiro Ohkuni; Hideki Makino; Yasutaka Kawamura; Shinji Motojima; Norihiro Kaneko
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2011-11

8.  Clinical diagnosis of hypersensitivity pneumonitis.

Authors:  Yves Lacasse; Moises Selman; Ulrich Costabel; Jean-Charles Dalphin; Masayuki Ando; Ferran Morell; Riitta Erkinjuntti-Pekkanen; Nestor Muller; Thomas V Colby; Mark Schuyler; Yvon Cormier
Journal:  Am J Respir Crit Care Med       Date:  2003-07-03       Impact factor: 21.405

9.  [Prognostic value of Charlson comorbidity index at 30 days and 1 year after acute myocardial infarction].

Authors:  Julio E Núñez; Eduardo Núñez; Lorenzo Fácila; Vicente Bertomeu; Angel Llàcer; Vicent Bodí; Juan Sanchis; Rafael Sanjuán; María L Blasco; Luciano Consuegra; Angel Martínez; Francisco J Chorro
Journal:  Rev Esp Cardiol       Date:  2004-09       Impact factor: 4.753

10.  Interstitial lung disease in systemic sclerosis.

Authors:  G C Ooi; M Y Mok; K W T Tsang; Y Wong; P L Khong; P C W Fung; S Chan; H F Tse; R W S Wong; W K Lam; C S Lau
Journal:  Acta Radiol       Date:  2003-05       Impact factor: 1.701

View more
  8 in total

1.  Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?

Authors:  Jun-Jun Yeh; Tuey-Wen Hung; Cheng-Li Lin; Tsung-Tse Chen; Pei-Xuan Liw; Ya-Lun Yu; Chia-Hung Kao
Journal:  Front Cardiovasc Med       Date:  2022-06-28

2.  Clinical utility of a composite scoring system including Charlson Comorbidity Index score in patients with interstitial lung disease.

Authors:  Hiroyuki Yagyu; Kota Murohashi; Yu Hara; Yusuke Saigusa; Ayako Aoki; Nobuaki Kobayashi; Takeshi Kaneko
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

3.  Serum heme oxygenase-1 measurement is useful for evaluating disease activity and outcomes in patients with acute respiratory distress syndrome and acute exacerbation of interstitial lung disease.

Authors:  Ryo Nagasawa; Yu Hara; Kota Murohashi; Ayako Aoki; Nobuaki Kobayashi; Shigeto Takagi; Satoru Hashimoto; Akihiko Kawana; Takeshi Kaneko
Journal:  BMC Pulm Med       Date:  2020-11-25       Impact factor: 3.317

4.  Predictive performance of comorbidity for 30-day and 1-year mortality in patients with bloodstream infection visiting the emergency department: a retrospective cohort study.

Authors:  Romy Schuttevaer; William Boogers; Anniek Brink; Willian van Dijk; Jurriaan de Steenwinkel; Stephanie Schuit; Annelies Verbon; Hester Lingsma; Jelmer Alsma
Journal:  BMJ Open       Date:  2022-04-06       Impact factor: 2.692

5.  Heme oxygenase-1 as an important predictor of the severity of COVID-19.

Authors:  Yu Hara; Jun Tsukiji; Aya Yabe; Yoshika Onishi; Haruka Hirose; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko; Toshiaki Ebina
Journal:  PLoS One       Date:  2022-08-24       Impact factor: 3.752

6.  Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease.

Authors:  Colin J Adams; Karan Chohan; Dmitry Rozenberg; John Kavanagh; Gerhard Greyling; Shane Shapera; Jolene H Fisher
Journal:  Lung       Date:  2021-08-04       Impact factor: 2.584

7.  Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases.

Authors:  Johanna Salonen; Minna Purokivi; Risto Bloigu; Riitta Kaarteenaho
Journal:  BMJ Open Respir Res       Date:  2020-04

8.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Authors:  Tao Zhang; Ping Shen; Chunyan Duan; Lingyun Gao
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.